Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oophorectomy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,303 result(s) found for: Oophorectomy. Displaying page 6 of 116.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2014-001589-85 Sponsor Protocol Number: D081FC00001 Start Date*: 2014-11-03
    Sponsor Name:Astrazeneca AB
    Full Title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr...
    Medical condition: Patients with gBRCA mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) NL (Completed) ES (Ongoing) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003273-66 Sponsor Protocol Number: ENX-CL-02-002 Start Date*: 2021-10-27
    Sponsor Name:Enlivex Therapeutics R&D Ltd.
    Full Title: A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ ...
    Medical condition: Sepsis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) FR (Completed) BE (Completed) GR (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003576-36 Sponsor Protocol Number: ARD11586(MM-121-04-02-08) Start Date*: 2012-04-20
    Sponsor Name:MERRIMACK PHARMACEUTICALS
    Full Title: A Phase II Randomized Open Label Study of MM-121 in combination with Paclitaxel versus Paclitaxel alone in patient with Platinum Resistant/Refractory Advanced Ovarian Cancers.
    Medical condition: Patient with Platinum Resistant/Refractory Advanced Ovarian Cancers.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) CZ (Completed) FR (Ongoing) ES (Ongoing) IT (Completed) NO (Completed) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004639-39 Sponsor Protocol Number: CYT003-QbG10 09 Start Date*: 2008-10-03
    Sponsor Name:Cytos Biotechnology AG
    Full Title: Double-blind, Placebo-controlled Dose-finding Study with CYT003-QbG10 in Adult Patients with Rhinoconjunctivitis due to House Dust Mite Allergy.
    Medical condition: Adult patients with perennial allergic rhinoconjunctivitis due to house dust mite
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) LV (Completed) LT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002778-30 Sponsor Protocol Number: CLAF237A2357 Start Date*: 2005-10-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaire...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001628-37 Sponsor Protocol Number: MO28231 Start Date*: 2012-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A TWO-COHORT, OPEN-LABEL, MULTICENTER, STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS WHO HAVE RECEIVED PRIOR ANTI-HER2 AND CHEMOTHERA...
    Medical condition: HER2 positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) SE (Completed) GB (Completed) DK (Completed) HU (Completed) PT (Completed) NO (Completed) AT (Completed) FI (Completed) IT (Completed) GR (Completed) IE (Completed) SI (Completed) BG (Completed) NL (Completed) EE (Completed) IS (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-006673-91 Sponsor Protocol Number: RD.03.SPR.40051 Start Date*: 2008-07-04
    Sponsor Name:GALDERMA R&D SNC
    Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CD5024 1% CREAM TREATMENT FOR UP TO 52 WEEKS IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA
    Medical condition: PATIENTS WITH PAPULOPUSTULAR ROSACEA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) HU (Completed) IS (Prematurely Ended) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002361-22 Sponsor Protocol Number: D5336C00001 Start Date*: 2017-12-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatm...
    Medical condition: Triple negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Ongoing) PL (Trial now transitioned) BE (Completed) FR (Completed) IE (Completed) NL (Completed) PT (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001565-33 Sponsor Protocol Number: RA101495-02.302 Start Date*: 2020-04-24
    Sponsor Name:Ra Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028415 Myasthenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003439-18 Sponsor Protocol Number: D0810C00019 Start Date*: 2009-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or mor...
    Medical condition: platinum sensitive serous ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) PL (Completed) CZ (Completed) ES (Completed) EE (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001685-38 Sponsor Protocol Number: 2693-CL-0312 Start Date*: 2021-11-24
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering from Moderate to Severe Vasomotor Symptoms (H...
    Medical condition: Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) ES (Ongoing) IT (Completed) HU (Completed) FI (Completed) NL (Completed) NO (Completed) DE (Completed) PL (Completed) DK (Completed) BE (Completed) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004420-35 Sponsor Protocol Number: GS-US-104-0423 Start Date*: 2013-02-13
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects
    Medical condition: Human Immunodeficiency Virus-1 (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) AT (Completed) NL (Completed) IT (Completed) IE (Completed) PT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001424-55 Sponsor Protocol Number: BCX7353-202 Start Date*: 2017-05-24
    Sponsor Name:BioCryst Pharmaceuticals Inc.
    Full Title: A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with heredi...
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) AT (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001243-36 Sponsor Protocol Number: BIA-2093-311/EXT Start Date*: 2015-11-06
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MU...
    Medical condition: Adult patients with recently diagnosed partial-onset seizures
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) LT (Completed) CZ (Completed) LV (Completed) PT (Completed) BE (Completed) FR (Completed) ES (Completed) SE (Completed) EE (Completed) AT (Completed) BG (Completed) SK (Completed) FI (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003863-40 Sponsor Protocol Number: D4193C00002 Start Date*: 2015-09-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or M...
    Medical condition: Recurrent or metastatic PD-L1-positive or negative squamous cell carcinoma of the head and neck (SCCHN).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BE (Completed) DE (Completed) ES (Completed) FR (Completed) PL (Completed) RO (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002163-24 Sponsor Protocol Number: M04-690 Start Date*: 2004-11-23
    Sponsor Name:Abbott Laboratories
    Full Title: A Multi-Centre Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to evaluate the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Croh...
    Medical condition: Crohn's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) SE (Completed) GB (Completed) ES (Completed) IT (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-000775-34 Sponsor Protocol Number: 01-04-TL-475-002 Start Date*: 2004-11-17
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A double-blind, randomised, parallel group study to evaluate the safety, tolerability and efficacy of TAK-475 alone or co-administered with atorvastatin in patients with primary dyslipidemia
    Medical condition: Treatment of patients with primary dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    7 10058108 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) CZ (Completed) EE (Completed) SK (Completed) LV (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016070-33 Sponsor Protocol Number: 6913-004 Start Date*: 2010-01-20
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase IIa, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal W...
    Medical condition: Vasomotor symptoms (hot flashes)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060800 Hot flush LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended) BE (Completed) SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005185-18 Sponsor Protocol Number: HEPA-CRV431-207 Start Date*: 2022-07-13
    Sponsor Name:Hepion Pharmaceuticals, Inc.
    Full Title: ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVAN...
    Medical condition: NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSIS
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004871 10086370 NASH with fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004228-41 Sponsor Protocol Number: C0251002 Start Date*: 2021-07-28
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 21:25:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA